Ataxia Market to Surpass US$ 47,360.7 Million by 2028

Global Ataxia Market, by Treatment Type (Pharmacotherapy (Levodopa, Pramipexole, Desvenlafaxine, Venlafaxine, and Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)), Physical Therapy, Speech Therapy, and Others (Adaptive Devices and Occupational Therapy)), by Disease Type (Friedreich's Ataxia, Ataxia-telangiectasia, Spinocerebellar Ataxias, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 30,880.5 million in 2021 and is expected to exhibit a CAGR of 9.4% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market are focusing on receiving product approvals from regulatory authorities and this is expected to drive the global ataxia market growth over the forecast period.

For instance, in November 2017, Jupiter Orphan Therapeutics, Inc., a U.S. based pharmaceutical company focusing on rare diseases received orphan drug designation from the U.S. Food and drug Administration (FDA) for its investigational drug JOTROL for the treatment of Friedreich’s ataxia (FA).

Global Ataxia Market – Impact of Coronavirus (Covid-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 235 million cases and 4.8 million deaths due to Coronavirus (COVID-19) were reported up till October 3, 2021, across the globe.

The COVID-19 pandemic is expected to positively impact global ataxia market owing to association of ataxia with COVID-19. For instance, according to an article published by the Movement Disorders Clinical Practice journal in March 2021, several neurological manifestations of COVID-19 have been reported globally that range from mild conditions such as headache, confusion, focal seizures, ataxia to severe life-threatening conditions such as Guillain Barre Syndrome, acute haemorrhagic necrotizing encephalopathy, and others.

Browse 33 Market Data Tables and 25 Figures spread through 150 Pages and in-depth TOC on “Ataxia Market”- Global Forecast to 2028, by Treatment Type (Pharmacotherapy (Levodopa, Pramipexole, Desvenlafaxine, Venlafaxine, and Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)), Physical Therapy, Speech Therapy, and Others (Adaptive Devices and Occupational Therapy)), by Disease Type (Friedreich's Ataxia, Ataxia-telangiectasia, Spinocerebellar Ataxias, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the global ataxia market, click the link below:

https://www.coherentmarketinsights.com/market-insight/ataxia-market-4714

Key players operating in the market are focusing on adoption of inorganic growth strategies such as collaborations and acquisitions, in order to strengthen their position in the global ataxia market. For instance, in April 2021, Healx, a Cambridge based biotechnology company announced collaboration with Ataxia UK, a patient support organisation for people suffering from ataxia and FARA (Friedreich’s Ataxia Research Alliance) to develop treatments for Friedreich’s ataxia.

Key Takeaways of the Global Ataxia Market:

• The global ataxia market is expected to exhibit a CAGR of 9.4% over the forecast period, owing to rapid research and development activities related to treatment of ataxia. For instance, in January 2019, Neurocrine Biosciences Inc., a U.S. based biopharmaceutical company and Voyager Therapeutics, a U.S. based biotechnology company announced collaboration for development and commercialisation of gene therapy VY-AADC and VY-FXN01 for treatment of Parkinson’s disease and Friedreich’s ataxia respectively.
• Among treatment type, pharmacotherapy segment is expected to account for largest market share in 2021, owing to market players focusing on obtaining drug approvals. For instance, in October 2019, Reata Pharmaceuticals, Inc., a U.S. based pharmaceutical company announced that it will seek regulatory approval from the U.S. FDA based on positive Phase II clinical trial results for its drug omaveloxolone in patients suffering from Friedreich’s ataxia.
• Key players operating in the global ataxia market include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan